Drug intelligence / Profile preview

Lipovax-Fg15-malaria

Development stage: Discontinued
Lead developer: Lipotek
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

Lipovax-Fg15-malaria is a preclinical-stage liposome-based vaccine developed by Lipotek Pty Ltd for the prevention of malaria. It is built on the Lipovax-Fg115 platform, which uses liposomes to deliver recombinant malaria antigens. The technology incorporates proprietary Fg115 (or Fg15) molecules that function as Toll-like receptor 5 (TLR5) agonists, facilitating the targeting and activation of dendritic cells to elicit a robust immune response. Antigens are attached to the liposome surface using histidine tags. Development of this candidate appears to have ceased, with no active reports identified since approximately 2020.

Other names: Lipotek malaria vaccine

Targets

TLR5

Beyond the preview

Go deeper on Lipovax-Fg15-malaria.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipovax-Fg15-malaria.

Explore the full profile